Vera Therapeutics’ Trutakna meets all prespecified endpoints in ORIGIN 3 IgA nephropathy trial
VERA•Vera Therapeutics said Trutakna met all prespecified efficacy endpoints in the ORIGIN 3 trial, slowing kidney function decline and reducing kidney disease progression risk versus placebo. The company plans to file a supplemental biologics license application in the fourth quarter of 2026, with potential full FDA approval in 2027.
1. Trial results
Vera Therapeutics reported positive final results from its ORIGIN 3 trial of Trutakna in adults with primary IgA nephropathy. The treatment met all prespecified efficacy endpoints, slowing kidney function decline and reducing the risk of kidney disease progression versus placebo; safety was generally comparable to placebo, with fewer serious adverse events.
2. Next steps
Results were presented at ASN Kidney Week 2026 on October 22 and published simultaneously in The New England Journal of Medicine. Vera Therapeutics plans to submit a supplemental biologics license application in the fourth quarter of 2026, with potential full FDA approval in 2027.
